Skip to main content
Sign In
 

Welcome to the Barbara Davis Center for Diabetes (BDC)


Barbara Davis Center for Diabetes

Mission:
Our mission is to provide state-of the-art care to children and adults with type 1 diabetes and to teach our patients how to prevent or delay complications. Our research is devoted to finding prevention, cure, and most effective treatment of diabetes and associated disorders.
Marian Rewers, MD, PhD
Executive Director 

The Barbara Davis Center for Diabetes (BDC) specializes in type 1 diabetes research and care for children and adults. It is one of the largest diabetes institutes in the world. The Center is part of the University of Colorado School of Medicine and has its dedicated building on the Anschutz Medical Campus  (map) in Aurora, Colorado. The Center was funded by Marvin Davis, in 1978, and is generously supported by the Children’s Diabetes Foundation (CDF)​.
Clinicians, clinical researchers, and basic biomedical scientists work at the BDC to find the most effective treatment, prevention, and cure for type 1 diabetes. The Center provides state-of-the-art diabetes care to 3600 children and 2400 adults with diabetes from the Rocky Mountain Region as well as receiving national and international referrals. We also provide inpatient care to patients who are seen at the Children’s Hospital Colorado with any type of diabetes.
The Center’s faculty teach the medical, physician assistant, nursing, and dental students on campus. Residents and endocrinology fellows train at the Center on elective rotations. Basic science faculty members provide mentorship to pre-doctoral students and post-doctoral fellows from around the world.




                  Childhood Diabetes Prevention Day Symposium:

General Population Screening for T1D

Shore Family Auditorium, Nighthorse Campbell Native Health Building

University of Colorado Anschutz Medical Campus

8-3:15, November 15, 2019


Type 1 diabetes (T1D) affects 1.3 million people in the U.S. The incidence continues to increase 3-5% annually. Clinical diagnosis is preceded by months or years of pre-symptomatic autoimmunity to pancreatic beta cells. Once multiple islet autoantibodies are present in children, they inevitably progress to diabetes.  The JDRF, the American Diabetes Association, and the Endocrine Society have recognized that T1D should be diagnosed when a child develops multiple islet autoantibodies (stage 1) irreversibly leading to dysglycemia (stage 2) and symptomatic hyperglycemia (stage 3 T1D). Symptoms of diabetes are often overlooked by parents and providers. 

The objectives of this symposium are: 

1) To discuss novel approaches in the prevention of T1D

2) To summarize current analyses of cost-effectiveness in the screening and prevention of T1D

3) To explore the role of genetic markers in the prediction of T1D

Speakers Include:

Gina Agiostratidou, Director, Helmsley Charitable Trust T1D Program

Jesse Bushman Senior Director of Health Policy, JDRF

Stephen Daniels, Chair, Department of Pediatrics, UC AMC

Jessica Dunne,  Director, JDRF Research Cure/Prevention

William Hagopian, Pacific Northwest Diabetes Research Institute

Thomas Hoerger & Carolina Barbosa, RTI International/CDC

Jeffrey Krischer, Director, Health Informatics Institute, University of South Florida

Francisco Leon & Leni Ramos, Provention Bio

Edwin Liu, Arleta Rewers & Marisa Stahl, Department of Pediatrics, UC AMC

Brett McQuinn, School of Pharmacy, UC AMC

Stephen Rich, Director, Center for Public Health Genomics, University of Virginia

Matt Sussman & Jennifer Benner, Boston Health Economics

Brigitte Frohnert, Andrea Steck, Todd Alonso, and Marian Rewers, Barbara Davis Center for Diabetes